HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PR5-LL-CM01

an inhibitor of protein arginine methyltransferase 5 (PRMT5); has antineoplastic activity

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - PR5-LL-CM01: 1
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - PR5-LL-CM01: 1
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - PR5-LL-CM01: 1

Experts

1.	Amaro, Rommie: 1 article (06/2017)
2.	Chen, Lan: 1 article (06/2017)
3.	Demir, Özlem: 1 article (06/2017)
4.	Fishel, Melissa: 1 article (06/2017)
5.	Korc, Murray: 1 article (06/2017)
6.	Lu, Tao: 1 article (06/2017)
7.	Mo, Jessica: 1 article (06/2017)
8.	Prabhu, Lakshmi: 1 article (06/2017)
9.	Safa, Ahmad: 1 article (06/2017)
10.	Sandusky, George: 1 article (06/2017)

Related Diseases

1.	Neoplasms (Cancer) 06/20/2017 - "Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers. " 06/20/2017 - "Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. "

Related Drugs and Biologics

1.	GSK3235025